Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.49 |
| ▸ | MME | P08473 | 5/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
| ▸ | BHMT | Q93088 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | ECE1 | P42892 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3341843 | 1.00 | LTA4H (0.49) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL10494263 | 1.00 | LTA4H (0.49) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL2807590 | 1.00 | LTA4H (0.49) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL3341838 | 1.00 | LTA4H (0.49) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL31170917 | 0.96 | LTA4H (0.46) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL30198622 | 0.96 | LTA4H (0.46) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL30797948 | 0.91 | GNPAT (0.46) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL29374714 | 0.90 | BACE1 (0.48) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL30408803 | 0.88 | PTPN1 (0.45) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL30317542 | 0.88 | BACE1 (0.43) | LTA4HMMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182519-A1 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | IPSEN PHARMA S.A.S. (FR) | 2024-06-06 | — | — | US | claimed |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | IPSEN PHARMA SAS (FR) | 2022-10-27 | — | — | US | claimed |
| EP-2599483-A1 | 4-Phenylbutyric acid formulation | Lunamed AG (CH) | 2013-06-05 | — | — | EP | claimed |
| US-20080213339-A1 | Pharmaceutical Composition Containing Indometacin and/or Acemetacin | DROSSAPHARM AG (CH) | 2008-09-04 | — | — | US | claimed |
| US-5631038-A | COMPOUNDS (TASTANDS) TO REDUCE OR ELIMINATE A BITTER OR METALLIC TASTE ARE ADDED TO FOODS CONTAINING SODIUM CHLORIDE | BIORESEARCH, INC. (US) | 1997-05-20 | — | — | US | claimed |
| EP-0728419-A2 | Ingestible containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers | BIORESEARCH, INC. (US) | 1996-08-28 | — | — | EP | claimed |
| EP-0661932-A4 | SPECIFIC EATABLE TASTE MODIFIERS. | BIORESEARCH INC (US) | 1996-06-05 | — | — | EP | claimed |
| EP-0661932-A1 | SPECIFIC EATABLE TASTE MODIFIERS | BIORESEARCH, INC. (US) | 1995-07-12 | — | — | EP | claimed |
| WO-1993010677-A1 | SPECIFIC EATABLE TASTE MODIFIERS | BIORESEARCH, INC. (US) | 1993-06-10 | — | — | WO | claimed |
| EP-0420539-A2 | Synergistic sweetening compositions containing a dipeptide sweetening agent and hydrogenated starch hydrolysates and methods for preparing same | WARNER-LAMBERT COMPANY (US) | 1991-04-03 | — | — | EP | claimed |
| US-4849541-A | Process for the preparation of N-L-aminodicarboxylic acid esters and new compositions used in the preparation thereof | GENERAL FOODS CORPORATION (US) | 1989-07-18 | — | — | US | claimed |
| US-4781927-A | Sweetening with l-aminodicarboxylic acid esters | GENERAL FOODS CORPORATION (US) | 1988-11-01 | — | — | US | claimed |
| EP-0256475-A2 | L-Aminodicarboxylic acid esters | GENERAL FOODS CORPORATION (US) | 1988-02-24 | — | — | EP | claimed |
| EP-0034876-B1 | BRANCHED AMIDES OF L-ASPARTYL-D-AMINO ACID DIPEPTIDES AND COMPOSITIONS THEREOF | PFIZER INC. (US) | 1984-08-29 | — | — | EP | claimed |
| EP-4711004-A2 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | Rhythm Pharmaceuticals, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4618952-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-4399163-A | ARTIFICIAL SWEETENERS | PFIZER INC. (US) | 1983-08-16 | — | — | US | disclosed |
| EP-0069811-A1 | Branched amides of L-aspartyl-D-amino acid dipeptides and compositions thereof | PFIZER INC. (US) | 1983-01-19 | — | — | EP | disclosed |
| EP-0034876-A2 | Branched amides of L-aspartyl-D-amino acid dipeptides and compositions thereof | PFIZER INC. (US) | 1981-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080213339-A1 | Pharmaceutical Composition Containing Indometacin and/or Acemetacin | ACE, IDO1, CMA1 | LTA4H 773/4885MME 11/4885ACE 1/4885 |
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | MC4R, NPY4R, MC3R | LTA4H 2562/4885MME 2376/4885ACE 2940/4885 |
| US-20240182519-A1 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | MC4R, MC3R, MC1R | LTA4H 533/4885MME 584/4885ACE 3654/4885 |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | MC4R, MC1R, MC3R | LTA4H 1006/4885MME 183/4885ACE 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.